A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas
Open accessAbstract
Half of all human cancers lose p53 function by missense mutations, with an unknown fraction of these containing p53 in a self-aggregated amyloid-like state. Here we show that a cell-penetrating peptide, ReACp53, designed to inhibit p53 amyloid formation, rescues p53 function in cancer cell lines and in organoids derived from high-grade serous ovarian carcinomas (HGSOC), an aggressive cancer characterized by ubiquitous p53 mutations. Rescued p53 behaves similarly to its wild-type counterpart in regulating target genes, reducing cell proliferation and increasing cell death. Intraperitoneal administration decreases tumor proliferation and shrinks xenografts in vivo. Our data show the effectiveness of targeting a specific aggregation defect of p53 and its potential applicability to HGSOCs.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Peptide ReACp53 prevents the amyloid-like aggregation of proteins with point mutations in p53-R248Q or p53-R175H.
“Peptide ReACp53 was described to prevent the amyloid-like aggregation of proteins with point mutations in p53-R248Q or p53-R175H.”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [134]
Treatment of ovarian cancer xenografts with ReACp53 resulted in decreased cell proliferation and tumor reduction.
“Treatment of ovarian cancer xenografts with ReACp53 resulted in decreased cell proliferation and tumor reduction [134].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [134]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
1 retracted
Janzen, D. M., Tiourin, E., Salehi, J. A., Paik, D. Y., Lu, J. N., Pellegrini, M. A., & Memarzadeh, S. (2015) · Nature Communications · doi:10.1038/ncomms8956 · Cited by 68 · see citing works
Self-citationRetractedSiegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499 · see citing works
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927 · see citing works
Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature
Park, P. Y., Goldin, T. A., Chang, J. C. S., Markman, M. M., & Kundranda, M. N. (2015) · Case Reports in Oncology · doi:10.1159/000441772 · Cited by 5,273 · see citing works
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · see citing works
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335 · see citing works
T antigen is bound to a host protein in SY40-transformed cells
Lane, D. P., & Crawford, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,443 · see citing works
Atomic structures of amyloid cross-β spines reveal varied steric zippers
Sawaya, M. R., Sambashivan, S., Nelson, R. A., Ivanova, M. I., Sievers, S. A., Apostol, M. I., Thompson, M. J., Balbirnie, M., Wiltzius, J. J. W., McFarlane, H. T., et al. (2007) · Nature · doi:10.1038/nature05695 · Cited by 2,279 · see citing works
Self-citationThe first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967 · see citing works
Leaver-Fay (2011) · doi:10.1016/b978-0-12-381270-4.00019-6 · Cited by 1,904 · see citing works
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · see citing works
Linzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,814 · see citing works
The Amyloid State of Proteins in Human Diseases
Eisenberg, D. S., & Jucker, M. (2012) · Cell · doi:10.1016/j.cell.2012.02.022 · Cited by 1,732 · see citing works
Self-citationMuller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647 · see citing works
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · cited 3× · see citing works
“With thousands of different p53 mutations described (IARC TP53 database, http://p53.iarc.fr) (Petitjean et al., 2007), we cannot yet anticipate which will respond to ReACp53, other than the well-established aggregation-prone mutations.”
BackgroundInfluentialRethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I. G., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. P., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3144 · Cited by 1,470 · see citing works
Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins
Anderson, L., & Hunter, C. L. (2006) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m500331-mcp200 · Cited by 1,230 · see citing works
P53 in survival, death and metabolic health: a lifeguard with a licence to kill.
Kruiswijk, F., Labuschagne, C. F., & Vousden, K. H. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4007 · Cited by 1,080 · see citing works
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · see citing works
Vousden, K. H., & Ryan, K. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2715 · Cited by 959 · see citing works
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway
Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.017 · Cited by 865 · see citing works
Identifying the amylome, proteins capable of forming amyloid-like fibrils
Goldschmidt, L., Teng, P. K., Riek, R., & Eisenberg, D. S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915166107 · Cited by 810 · see citing works
Self-citationDriver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
Ahmed, A. A., Etemadmoghadam, D., Temple, J., Lynch, A. G., Riad, M., Sharma, R. N., Stewart, C. J. R., Fereday, S., Caldas, C., DeFazio, A., et al. (2010) · The Journal of Pathology · doi:10.1002/path.2696 · Cited by 786 · see citing works
Drugging the p53 pathway: understanding the route to clinical efficacy
Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 723 · see citing works
Structural Biology of the Tumor Suppressor p53
Joerger, A. C., & Fersht, A. R. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.060806.091238 · Cited by 699 · see citing works
The genetics of the p53 pathway, apoptosis and cancer therapy
Vázquez, A., Bond, E. E., Levine, A. J., & Bond, G. L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2656 · Cited by 674 · see citing works
Rescuing the function of mutant p53
Bullock, A. N., & Fersht, A. R. (2001) · Nature reviews. Cancer · doi:10.1038/35094077 · Cited by 565 · see citing works
The Histologic Type and Stage Distribution of Ovarian Carcinomas of Surface Epithelial Origin
Seidman, J. D., Horkayne‐Szakaly, I., Haiba, M., Boice, C. R., Kurman, R. J., & Ronnett, B. M. (2003) · International Journal of Gynecological Pathology · doi:10.1097/01.pgp.0000101080.35393.16 · Cited by 555 · see citing works
Gain of function of mutant p53 by coaggregation with multiple tumor suppressors
Xu, J., Reumers, J., Couceiro, J. R., De Smet, F., Gallardo, R., Rudyak, S., Cornelis, A., Rozenski, J., Zwolinska, A., Marine, J.-C., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.546 · Cited by 543 · see citing works
Ovarian Cancer Metastasis: Integrating insights from disparate model organisms
Naora, H., & Montell, D. J. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1611 · Cited by 538 · see citing works
Pathogenesis of Ovarian Cancer
Kurman, R. J., & Shih, I. (2008) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e318161e4f5 · Cited by 460 · see citing works
Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation
Sievers, S. A., Karanicolas, J., Chang, H. W., Zhao, A., Jiang, L., Zirafi, O., Stevens, J. T., Münch, J., Baker, D. A., & Eisenberg, D. S. (2011) · Nature · doi:10.1038/nature10154 · Cited by 459 · see citing works
Self-citationChang, S., Hodeib, M., Chang, J. J., & Bristow, R. E. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.05.040 · Cited by 434 · see citing works
Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406 · see citing works
Thermodynamic stability of wild-type and mutant p53 core domain
Bullock, A. N., Henckel, J., DeDecker, B. S., Johnson, C. M., Nikolova, P. V., Proctor, M. R., Lane, D. P., & Fersht, A. R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.26.14338 · Cited by 405 · see citing works
Allele-Specific p53 Mutant Reactivation
Yu, X., Vázquez, A., Levine, A. J., & Carpizo, D. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.042 · Cited by 320 · see citing works
Inhibition of Amyloid Formation
Härd, T., & Lendel, C. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.12.062 · Cited by 266 · see citing works
Small molecule induced reactivation of mutant p53 in cancer cells
Liu, X., Wilcken, R., Joerger, A. C., Chuckowree, I., Amin, J., Spencer, J., & Fersht, A. R. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt305 · Cited by 235 · see citing works
Prion-like aggregation of mutant p53 in cancer
Silva, J. L., Gallo, C. V. D. M., da Costa, D. C. F., & Rangel, L. P. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.04.001 · Cited by 202 · see citing works
Ovarian Cancer, Version 3.2012
Morgan, R. J., Alvarez, R. D., Armstrong, D. K., Burger, R. A., Castells, M., Chen, L.-M., Copeland, L. J., Crispens, M. A., Gershenson, D. M., Gray, H. J., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0140 · Cited by 195 · see citing works
Martirosyan, A., Clendening, J. W., Goard, C. A., & Penn, L. Z. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-103 · Cited by 161 · see citing works
Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors
Levy, C. B., Stumbo, A. C., Bom, A. P. D. A., Portari, E. A., Carneiro, Y., Silva, J. L., & Gallo, C. V. D. M. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.10.017 · Cited by 150 · see citing works
Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide
Issaeva, N., Friedler, A., Bozko, P. M., Wiman, K. G., Fersht, A. R., & Selivanova, G. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1835733100 · Cited by 144 · see citing works
Ovarian Cancer, Version 2.2013
Morgan, R. J., Alvarez, R. D., Armstrong, D. K., Burger, R. A., Chen, L.-M., Copeland, L. J., Crispens, M. A., Gershenson, D. M., Gray, H. J., Hakam, A., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0142 · Cited by 142 · see citing works
Rufini, A., Agostini, M., Grespi, F., Tomasini, R., Sayan, B. S., Niklison-Chirou, M. V., Conforti, F., Velletri, T., Mastino, A., Mak, T. W., et al. (2011) · Genes & Cancer · doi:10.1177/1947601911408890 · Cited by 138 · see citing works
Polyarginine as a multifunctional fusion tag
Fuchs, S. M., & Raines, R. T. (2005) · Protein Science · doi:10.1110/ps.051393805 · Cited by 128 · see citing works
Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition
Wilcken, R., Wang, G., Boeckler, F. M., & Fersht, A. R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211550109 · Cited by 120 · see citing works
L'Espérance, S., Bachvarova, M., Tetu, B., Mes-Masson, A.-M., & Bachvarov, D. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-99 · Cited by 108 · see citing works
Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma
LEITAO, M., Soslow, R. A., Baergen, R. N., Olvera, N., ARROYO, C., & Boyd, J. A. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.01.043 · Cited by 88 · see citing works
Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity
Lasagna‐Reeves, C. A., Clos, A. L., Castillo‐Carranza, D. L., Sengupta, U., Guerrero‐Munoz, M. J., Kelly, B. C., Wagner, R. F., & Kayed, R. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.11.130 · Cited by 86 · see citing works
Vossio, S., Palescandolo, E., Pediconi, N., Moretti, F., Balsano, C., Levrero, M., & Costanzo, A. (2002) · Oncogene · doi:10.1038/sj.onc.1205465 · Cited by 78 · see citing works
First-order rate-determining aggregation mechanism of p53 and its implications
Wang, G., & Fersht, A. R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211557109 · Cited by 71 · see citing works
Investigating the Intrinsic Aggregation Potential of Evolutionarily Conserved Segments in p53
Ghosh, S., Ghosh, D., Ranganathan, S., Arunagiri, A., Palanirajan, S. K., Jha, N. N., Padinhateeri, R., & Maji, S. K. (2014) · Biochemistry · doi:10.1021/bi500825d · Cited by 67 · see citing works
P73 gene expression in ovarian cancer tissues and cell lines.
Chen, C., Ip, S.-M., Cheng, D., Wong, L. C., & Ngan, H. (2000) · PubMed · Cited by 53 · see citing works
Alendronate Inhibits Intraperitoneal Dissemination in In vivo Ovarian Cancer Model
Hashimoto, K., Morishige, K.-I., Sawada, K., Tahara, M., Kawagishi, R., Ikebuchi, Y., Sakata, M., Tasaka, K., & Murata, Y. (2005) · Cancer Research · doi:10.1158/0008-5472.540.65.2 · Cited by 49 · see citing works
p53 Inactivation Upregulates p73 Expression through E2F-1 Mediated Transcription
Tophkhane, C., Yang, S., Jiang, Y., Ma, Z., Subramaniam, D., Anant, S., Yogosawa, S., Sakai, T., Liu, W., Edgerton, S. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043564 · Cited by 37 · see citing works
Rieber, M., & Strasberg–Rieber, M. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.09.003 · Cited by 30 · see citing works
Knight, L. A., Kurbacher, C. M., Glaysher, S., Fernando, A., Reichelt, R., Dexel, S., Reinhold, U., & Cree, I. A. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-38 · Cited by 30 · see citing works
Allele specific gain-of-function activity of p53 mutants in lung cancer cells
Vaughan, C. A., Frum, R. A., Pearsall, I., Singh, S., Windle, B. E., Yeudall, W. A., Deb, S. P., & Deb, S. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.09.029 · Cited by 27 · see citing works
Newton, T. R., Parsons, P. G., Lincoln, D. J., Cummings, M. C., Wyld, D., Webb, P. M., Green, A. C., & Boyle, G. M. (2006) · International Journal of Cancer · doi:10.1002/ijc.21823 · Cited by 22 · see citing works
Flagged first, then by citations
1 of the 61 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Protein Phase Separation: A New Phase in Cell Biology
Boeynaems, S., Alberti, S., Fawzi, N. L., Mittag, T., Polymenidou, M., Rousseau, F., Schymkowitz, J. W. H., Shorter, J., Wolozin, B. L., Bosch, L. V. D., et al. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.02.004 · Cited by 1,954 · see citing works
Kastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906 · see citing works
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016 · see citing works
Targeting mutant p53 for efficient cancer therapy
Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889 · see citing works
Drugging p53 in cancer: one protein, many targets
Hassin, O., & Oren, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00571-8 · Cited by 736 · see citing works
The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches
Joerger, A. C., & Fersht, A. R. (2016) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014710 · Cited by 658 · see citing works
Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours
Yao, H., Lan, J., Li, C., Shi, H., Brosseau, J., Wang, H., Lu, H., Fang, C., Zhang, Y., Liang, L., et al. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0375-6 · Cited by 572 · see citing works
Targeting mutant p53 for cancer therapy: direct and indirect strategies
Hu, J., Cao, J., Topatana, W., Juengpanich, S., Li, S., Zhang, B., Shen, J., Cai, L., Cai, X., & Chen, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01169-0 · Cited by 557 · see citing works
Structural Studies of Amyloid Proteins at the Molecular Level
Eisenberg, D. S., & Sawaya, M. R. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045104 · Cited by 513 · see citing works
Self-citationTherapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517 · see citing works
The activities of amyloids from a structural perspective
Riek, R., & Eisenberg, D. S. (2016) · Nature · doi:10.1038/nature20416 · Cited by 504 · see citing works
Self-citationUnderstanding the complexity of p53 in a new era of tumor suppression
Liu, Y., Su, Z., Tavana, O., & Gu, W. J. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.04.009 · Cited by 519 · see citing works
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation
Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05408-1 · Cited by 494 · see citing works
Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246
Cooks, T., Pateras, I. S., Jenkins, L. M. M., Patel, K., Robles, A. I., Morris, J., Forshew, T., Appella, E., Gorgoulis, V. G., & Harris, C. C. (2018) · Nature Communications · doi:10.1038/s41467-018-03224-w · Cited by 483 · see citing works
The p53 Pathway in Glioblastoma
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440 · see citing works
Mutant p53 as a target for cancer treatment
Duffy, M. J., Synnott, N. C., & Crown, J. P. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.023 · Cited by 361 · see citing works
Zhou, G., Liu, Z., & Myers, J. N. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25592 · Cited by 344 · see citing works
Phase Separation: Linking Cellular Compartmentalization to Disease
Aguzzi, A., & Altmeyer, M. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.03.004 · Cited by 333 · see citing works
Gain-of-function mutant p53 in cancer progression and therapy
Zhang, C., Liu, J., Xu, D., Zhang, T., Hu, W., & Feng, Z. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa040 · Cited by 339 · see citing works
Prions, prionoids and protein misfolding disorders
Scheckel, C., & Aguzzi, A. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0011-4 · Cited by 308 · see citing works
Mechanisms and Functions of Spatial Protein Quality Control
Sontag, E. M., Samant, R. S., & Frydman, J. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014616 · Cited by 269 · see citing works
Phan, N., Hong, J. J., Tofig, B., Mapua, M., Elashoff, D., Moatamed, N. A., Huang, J., Memarzadeh, S., Damoiseaux, R., & Soragni, A. (2019) · Communications Biology · doi:10.1038/s42003-019-0305-x · Cited by 269 · see citing works
Self-citationAtomic structures of TDP-43 LCD segments and insights into reversible or pathogenic aggregation
Guenther, E. L., Cao, Q., Trinh, H., Lu, J., Sawaya, M. R., Cascio, D., Boyer, D. R., Rodríguez, J. A., Hughes, M. P., & Eisenberg, D. S. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0064-2 · Cited by 247 · see citing works
Self-citationMutant p53 in cancer therapy—the barrier or the path
Zhou, X. Y., Hao, Q., & Lu, H. (2018) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy072 · Cited by 244 · see citing works
Mutant p53 in Cancer Progression and Targeted Therapies
Zhu, G., Pan, C., Bei, J., Li, B., Chen, L., Xu, Y., & Fu, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.595187 · Cited by 222 · see citing works
TP53 gain-of-function mutation promotes inflammation in glioblastoma
Ham, S. W., Jeon, H.-Y., Jin, X., Kim, E.-J., Kim, J.-K., Shin, Y. J., Lee, Y., Kim, S. H., Lee, S. Y., Seo, S., et al. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0126-3 · Cited by 213 · see citing works
Treating p53 Mutant Aggregation-Associated Cancer
Kanapathipillai, M. (2018) · Cancers · doi:10.3390/cancers10060154 · Cited by 211 · see citing works
Balasubramanian, A., Hsu, A. Y.-H., Ghimire, L., Tahir, M., Devant, P., Fontana, P., Du, G., Liu, X., Dang, F., Kambara, H., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adn1452 · Cited by 210 · see citing works
Translating p53-based therapies for cancer into the clinic
Peuget, S., Zhou, X., & Selivanova, G. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-023-00658-3 · Cited by 198 · see citing works
Uversky, V. N. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111874 · Cited by 193 · see citing works
Han, Y., Kim, B., Cho, U., Park, I. S., Kim, S. I., Dhanasekaran, D. N., Tsang, B. K., & Song, Y. S. (2019) · Oncogene · doi:10.1038/s41388-019-0949-5 · Cited by 188 · see citing works
Amyloid assembly and disassembly
Chuang, E., Hori, A. M., Hesketh, C. D., & Shorter, J. (2018) · Journal of Cell Science · doi:10.1242/jcs.189928 · Cited by 182 · see citing works
Targeting the DNA Damage Response in OSCC with TP 53 Mutations
Lindemann, A., Takahashi, H., Patel, A. A., Osman, A. A., & Myers, J. N. (2018) · Journal of Dental Research · doi:10.1177/0022034518759068 · Cited by 163 · see citing works
Exploring the multiple roles of guardian of the genome: P53
Feroz, W., & Sheikh, A. M. A. (2020) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-020-00089-x · Cited by 161 · see citing works
TP53 mutations in epithelial ovarian cancer
Zhang, Y., Cao, L., Nguyen, D., & Lu, H. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.08.40 · Cited by 149 · see citing works
YY1 regulates cancer cell immune resistance by modulating PD-L1 expression
Hays, E., & Bonavida, B. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.04.001 · Cited by 144 · see citing works
How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance
Stiewe, T., & Haran, T. E. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.05.001 · Cited by 139 · see citing works
Fundamentals of cross-seeding of amyloid proteins: an introduction
Ren, B., Zhang, Y., Zhang, M., Liu, Y., Zhang, D., Gong, X., Feng, Z., Tang, J., Chang, Y., & Zheng, J. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb01871a · Cited by 135 · see citing works
p53 amyloid formation leading to its loss of function: implications in cancer pathogenesis
Ghosh, S., Salot, S., Sengupta, S., Navalkar, A., Ghosh, D., Jacob, R. S., Das, S., Kumar, R., Jha, N. N., Sahay, S., et al. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.105 · Cited by 136 · see citing works
Phase-to-Phase With Nucleoli – Stress Responses, Protein Aggregation and Novel Roles of RNA
Latonen, L. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00151 · Cited by 134 · see citing works
O -GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation
Zhu, Q., Wang, H., Chai, S., Xu, L., Lin, B., Yi, W., & Wu, L. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2216796120 · Cited by 132 · see citing works
Palanikumar, L., Karpauskaite, L., Al‐Sayegh, M., Chehade, I., Alam, M., Hassan, S., Maity, D., Ali, L., Kalmouni, M., Hunashal, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23985-1 · Cited by 127 · see citing works
Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer
Silva, J. L., Cino, E. A., Soares, I. N., Ferreira, V. F., & de Oliveira, G. A. P. (2017) · Accounts of Chemical Research · doi:10.1021/acs.accounts.7b00473 · Cited by 121 · see citing works
Structure-based inhibitors of amyloid beta core suggest a common interface with tau
Griner, S. L., Seidler, P., Bowler, J., Murray, K. A., Yang, T. P., Sahay, S., Sawaya, M. R., Cascio, D., Rodriguez, J. A., Philipp, S., et al. (2019) · eLife · doi:10.7554/elife.46924 · Cited by 121 · see citing works
Self-citationYang, Z., Xu, H., & Zhao, X. (2020) · Advanced Science · doi:10.1002/advs.201903718 · Cited by 120 · see citing works
Atomic-level evidence for packing and positional amyloid polymorphism by segment from TDP-43 RRM2
Guenther, E. L., Ge, P., Trinh, H., Sawaya, M. R., Cascio, D., Boyer, D. R., Gonen, T., Zhou, Z. H., & Eisenberg, D. S. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0045-5 · Cited by 121 · see citing works
Self-citationThe Function of the Mutant p53-R175H in Cancer
Chiang, Y.-T., Chien, Y., Lin, Y., Wu, H.-H., Lee, D., & Yu, Y. (2021) · Cancers · doi:10.3390/cancers13164088 · Cited by 119 · see citing works
Targeting Intrinsically Disordered Transcription Factors: Changing the Paradigm
Tsafou, K., Tiwari, P. B., Forman-Kay, J. D., Metallo, S. J., & Toretsky, J. A. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.04.008 · Cited by 110 · see citing works
Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5
Vogiatzi, F., Brandt, D. T., Schneikert, J., Fuchs, J., Grikscheit, K., Wanzel, M., Pavlakis, E., Charles, J. P., Timofeev, O., Nist, A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612711114 · Cited by 99 · see citing works
Ethical issues in human organoid and gastruloid research
Munsie, M., Hyun, I., & Sugarman, J. (2017) · Development · doi:10.1242/dev.140111 · Cited by 111 · see citing works
Rising horizon in circumventing multidrug resistance in chemotherapy with nanotechnology
Choudhury, H., Pandey, M., Yin, T. H., Kaur, T., Jia, G. W., Tan, S. Q. L., Weijie, H., Yang, E. K. S., Keat, C. G., Bhattamisra, S. K., et al. (2019) · Materials Science and Engineering C · doi:10.1016/j.msec.2019.04.005 · Cited by 107 · see citing works
Phase separation of p53 precedes aggregation and is affected by oncogenic mutations and ligands
Petronilho, E. C., Pedrote, M. M., Marques, M. A., Passos, Y. M., Mota, M. F., Jakobus, B., de Sousa, G. D. S., da Costa, F. P., Felix, A. L., Ferretti, G. D. S., et al. (2021) · Chemical Science · doi:10.1039/d1sc01739j · Cited by 107 · see citing works
Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target
Schulz‐Heddergott, R., & Moll, U. M. (2018) · Cancers · doi:10.3390/cancers10060188 · Cited by 105 · see citing works
Li, C., Wan, Y., Zhang, Y., Fu, L., Blum, N. T., Cui, R., Wu, B., Zheng, R., Lin, J., Li, Z., et al. (2021) · Advanced Materials · doi:10.1002/adma.202103980 · Cited by 104 · see citing works
Aberrant phase separation and cancer
Taniue, K., & Akimitsu, N. (2021) · FEBS Journal · doi:10.1111/febs.15765 · Cited by 99 · see citing works
Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition
Saelices, L., Chung, K., Lee, J. H., Cohn, W., Whitelegge, J. P., Benson, M. D., & Eisenberg, D. S. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805131115 · Cited by 98 · see citing works
Self-citationPeptides/Proteins Encoded by Non-coding RNA: A Novel Resource Bank for Drug Targets and Biomarkers
Zhu, S., Wang, J., He, Y., Meng, N., & Yan, G. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01295 · Cited by 96 · see citing works
Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors
Li, H., Zhang, J., TONG, J. H. M., Chan, A. W. H., Yu, J. Q., Kang, W., & To, K. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235999 · Cited by 96 · see citing works
Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy
Song, B., Yang, P., & Zhang, S. (2024) · 癌症：英文版 · doi:10.1002/cac2.12520 · Cited by 97 · see citing works
Sun, Y., & Chakrabartty, A. (2017) · Biochemistry · doi:10.1021/acs.biochem.6b01088 · Cited by 96 · see citing works
Biomolecular condensates: new opportunities for drug discovery and RNA therapeutics
Conti, B. A., & Oppikofer, M. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.07.001 · Cited by 90 · see citing works
Rangel, L. P., Ferretti, G. D. S., Costa, C. L., Andrade, S. M. M. V., Carvalho, R. S., da Costa, D. C. F., & Silva, J. L. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004671 · Cited by 89 · see citing works
Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease?Preprint
da Costa, D. C. F., de Oliveira, G. A. P., Cino, E. A., Soares, I. N., Rangel, L. P., & Silva, J. L. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a023614 · Cited by 89 · see citing works
Resveratrol prevents p53 aggregation in vitro and in breast cancer cells
da Costa, D. C. F., Campos, N., Santos, R. A., Guedes-da-Silva, F. H., Martins-Dinis, M. M. D. C., Zanphorlin, L. M., Ramos, C. H. I., Rangel, L. P., & Silva, J. L. (2018) · Oncotarget · doi:10.18632/oncotarget.25631 · Cited by 87 · see citing works
Oncogenic Gain of Function in Glioblastoma Is Linked to Mutant p53 Amyloid Oligomers
Pedrote, M. M., Motta, M. F., Ferretti, G. D. S., Norberto, D. R., Spohr, T. C. L. S., Lima, F. R. S., Gratton, E., Silva, J. L., & de Oliveira, G. A. P. (2020) · iScience · doi:10.1016/j.isci.2020.100820 · Cited by 89 · see citing works
Targeting Biomolecular Condensation and Protein Aggregation against Cancer
Silva, J. L., Foguel, D., Ferreira, V. F., Vieira, T. C. R. G., Marques, M. A., Ferretti, G. D. S., Outeiro, T. F., Cordeiro, Y., & de Oliveira, G. A. P. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00131 · Cited by 85 · see citing works
Multisite aggregation of p53 and implications for drug rescue
Wang, G., & Fersht, A. R. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700308114 · Cited by 82 · see citing works
Analysis and Interpretation of the Impact of Missense Variants in Cancer
Petrosino, M., Novak, L., Pasquo, A., Chiaraluce, R., Turina, P., Capriotti, E., & Consalvi, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115416 · Cited by 81 · see citing works
(2019) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2019.08.002 · Cited by 78 · see citing works
Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma
Flynt, E., Bisht, K. K., Sridharan, V., Ortiz, M., Towfic, F., & Thakurta, A. (2020) · Cells · doi:10.3390/cells9020287 · Cited by 76 · see citing works
Tumor suppressor p53: from engaging DNA to target gene regulation
Sammons, M. A., Nguyen, T., McDade, S. S., & Fischer, M. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa666 · Cited by 77 · see citing works
Personalized chordoma organoids for drug discovery studies
Al Shihabi, A., Davarifar, A., Nguyen, H. T. L., Tavanaie, N., Nelson, S. D., Yanagawa, J., Federman, N., Bernthal, N., Hornicek, F., & Soragni, A. (2022) · Science Advances · doi:10.1126/sciadv.abl3674 · Cited by 75 · see citing works
Self-citationDrug screening model meets cancer organoid technology
Liu, C., Qin, T., Huang, Y., Li, Y., Chen, G., & Sun, C. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100840 · Cited by 74 · see citing works
Exploring the relationships between protein sequence, structure and solubility
Trainor, K., Broom, A., & Meiering, E. M. (2017) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2017.01.004 · Cited by 74 · see citing works
Frederick, K. K., Michaelis, V. K., Caporini, M. A., Andreas, L. B., Debelouchina, G. T., Griffin, R. G., & Lindquist, S. L. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1619051114 · Cited by 70 · see citing works
Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer
Zhang, S., Carlsen, L., Borrero, L. J. H., Seyhan, A. A., Tian, X., & El‐Deiry, W. S. (2022) · Biomolecules · doi:10.3390/biom12040548 · Cited by 71 · see citing works
Smet, F. D., Rubio, M. S., Hompes, D., Naus, E., Baets, G. D., Langenberg, T., Hipp, M. S., Houben, B., Claes, F., Charbonneau, S. K., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4872 · Cited by 70 · see citing works
Anomalous Dense Liquid Condensates Host the Nucleation of Tumor Suppressor p53 Fibrils
Safari, M. S., Wang, Z., Tailor, K., Kolomeisky, A. B., Conrad, J. C., & Vekilov, P. G. (2019) · iScience · doi:10.1016/j.isci.2019.01.027 · Cited by 69 · see citing works
The “Jekyll and Hyde” Actions of Nucleic Acids on the Prion-like Aggregation of Proteins
Silva, J. L., & Cordeiro, Y. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.r116.733428 · Cited by 67 · see citing works
Patient-Derived Organoids as a Model for Cancer Drug Discovery
Rae, C. J., Amato, F., & Braconi, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073483 · Cited by 68 · see citing works
da Costa, D. C. F., Fialho, E., & Silva, J. L. (2017) · Molecules · doi:10.3390/molecules22061014 · Cited by 66 · see citing works
It’s Getting Complicated—A Fresh Look at p53-MDM2-ARF Triangle in Tumorigenesis and Cancer Therapy
Kung, C.-P., & Weber, J. D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.818744 · Cited by 68 · see citing works
Wawrzynów, B., Żylicz, M., & Żylicz, M. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.12.004 · Cited by 65 · see citing works
Mesoscopic protein-rich clusters host the nucleation of mutant p53 amyloid fibrils
Yang, D. S., Saeedi, A., Davtyan, A., Fathi, M., Sherman, M. B., Safari, M. S., Klindziuk, A., Barton, M. C., Varadarajan, N., Kolomeisky, A. B., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2015618118 · Cited by 63 · see citing works
Structural and Drug Targeting Insights on Mutant p53
Gomes, A. S., Ramos, H., Inga, A., Sousa, E., & Saraiva, L. (2021) · Cancers · doi:10.3390/cancers13133344 · Cited by 63 · see citing works
The algal polysaccharide ulvan suppresses growth of hepatoma cells
Zhao, C., Lin, G., Wu, D., Liu, D., You, L., Högger, P., Simal‐Gándara, J., Wang, M., da Costa, J. G. M., Marunaka, Y., et al. (2020) · Food Frontiers · doi:10.1002/fft2.13 · Cited by 62 · see citing works
Aggregation tendencies in the p53 family are modulated by backbone hydrogen bonds
Cino, E. A., Soares, I. N., Pedrote, M. M., de Oliveira, G. A. P., & Silva, J. L. (2016) · Scientific Reports · doi:10.1038/srep32535 · Cited by 62 · see citing works
Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket
Pradhan, M. R., Siau, J. W., Kannan, S., Nguyen, M. N., Ouaray, Z., Kwoh, C. K., Lane, D. P., Ghadessy, F. J., & Verma, C. S. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1314 · Cited by 62 · see citing works
Functional Mammalian Amyloids and Amyloid-Like Proteins
Rubel, M. S., Fedotov, S. A., Grizel, A. V., Sopova, J. V., Malikova, O. A., Chernoff, Y. O., & Rubel, A. A. (2020) · Life · doi:10.3390/life10090156 · Cited by 61 · see citing works
Krotee, P., Griner, S. L., Sawaya, M. R., Cascio, D., Rodríguez, J. A., Shi, D., Philipp, S., Murray, K. A., Saelices, L., Lee, J. H., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.806109 · Cited by 61 · see citing works
Self-citationAutophagy as an emerging therapy target for ovarian carcinoma
Zhan, L., Zhang, Y., Wang, W., Song, E., Fan, Y., Li, J., & Wei, B. (2016) · Oncotarget · doi:10.18632/oncotarget.13080 · Cited by 60 · see citing works
Exploring Dysregulated Signaling Pathways in Cancer.
Nisar, S., Hashem, S., Macha, M., Yadav, S., Muralitharan, S., Therachiyil, L., Sageena, G., Al-Naemi, H., Haris, M., & Bhat, A. (2020) · Current pharmaceutical design · doi:10.2174/1381612826666200115095937 · Cited by 42 · see citing works
Prion-like p53 Amyloids in Cancer
Navalkar, A., Ghosh, S., Pandey, S., Paul, A., Datta, D., & Maji, S. K. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00796 · Cited by 56 · see citing works
The Status of p53 Oligomeric and Aggregation States in Cancer
de Oliveira, G. A. P., Petronilho, E. C., Pedrote, M. M., Marques, M. A., Vieira, T. C. R. G., Cino, E. A., & Silva, J. L. (2020) · Biomolecules · doi:10.3390/biom10040548 · Cited by 57 · see citing works
Identification of Small Molecules that Modulate Mutant p53 Condensation
Lemos, C., Schulze, L., Weiske, J., Meyer, H., Braeuer, N., Barak, N. N., Eberspächer, U., Werbeck, N. D., Stresemann, C., Lange, M., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101517 · Cited by 56 · see citing works
Kehrloesser, S., Osterburg, C., Tuppi, M., Schäfer, B., Vousden, K. H., & Dötsch, V. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.75 · Cited by 56 · see citing works
Intracellularly Swollen Polypeptide Nanogel Assists Hepatoma Chemotherapy
Shi, B., Huang, K., Ding, J., Xu, W., Yu, Y., Liu, H., Yan, L., & Chen, X. (2017) · Theranostics · doi:10.7150/thno.16794 · Cited by 55 · see citing works
Organoid of ovarian cancer: genomic analysis and drug screening
Liu, H., Xia, B., Jin, M., & Lou, G. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02276-8 · Cited by 55 · see citing works
A NO/ROS/RNS cascaded-releasing nano-platform for gas/PDT/PTT/immunotherapy of tumors
Ding, M., Shao, K., Wu, L., Jiang, Y., Cheng, B., Wang, L., Shi, J., & Kong, X. (2021) · Biomaterials Science · doi:10.1039/d1bm00726b · Cited by 54 · see citing works
Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition
Iwanicki, M., Chen, H., Iavarone, C., Zervantonakis, I. K., Muranen, T. E., Novak, M., Ince, T. A., Drapkin, R., & Brugge, J. S. (2016) · JCI Insight · doi:10.1172/jci.insight.86829 · Cited by 54 · see citing works
- Authors
- Soragni, A., Janzen, D. M., Johnson, L. M., Lindgren, A. G., Thai-Quynh Nguyen, A., Tiourin, E., Soriaga, A. B., Lu, J., Jiang, L., Faull, K. F., Pellegrini, M., Memarzadeh, S., & Eisenberg, D. S.
- Affiliations
- Howard Hughes Medical Institute (US)
- University of California, Los Angeles (US)
- Corresponding author
- Memarzadeh, Sanaz
- Eisenberg, David S.
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2016-01
- Volume
- 29
- Issue
- 1
- Pages
- 90-103
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC4733364
- OpenAlex
- W2207474307
- Cited by
- 341
- References
- 61
- Citations by year
- 2026: 17 · 2025: 25 · 2024: 29 · 2023: 31 · 2022: 42 · 2021: 29 · 2020: 32 · 2019: 35 · 2018: 39 · 2017: 33 · 2016: 28
- FWCI
- 13.39
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- NIH (1S10RR023718-01A2, AG-029430, R01CA183877)
- Pardee Foundation
- National Center for Advancing Translational Science (UL1TR000124)
- American Cancer Society (RSG-14-217-01-TBG)
- National Science Foundation (MCB 0958111)
- Jonsson Cancer Center Foundation
- Lynne Cohen Foundation
- Phase One Foundation
- Ovarian Cancer Circle Inspired by Robin Babbini
- Leath L. and Marcia L. Millen Family Fund
- G.O. Discovery Lab Foundation
- HHMI
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- p53, amyloid-like aggregation, p53 missense mutations, cell-penetrating peptides, high-grade serous ovarian cancer, organoids, xenografts, cell proliferation, apoptosis
- MeSH terms
- Animals, Cell Line, Cells, Cultured, Disease Models, Animal, Female, Humans, Mice, Transgenic, Ovarian Neoplasms, Tumor Suppressor Protein p53, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
